RSLS - ReShape Lifesciences - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

RSLS is currently covered by 1 analysts with an average price target of $-56295.69. This is a potential upside of $-56300 (-1306264.5%) from yesterday's end of day stock price of $4.31.

ReShape Lifesciences's activity chart (see below) currently has 10 price targets and 16 ratings on display. The stock rating distribution of RSLS is 100% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 50% with an average time for these price targets to be met of 124.5 days.

Highest price target for RSLS is $338, Lowest price target is $338.

Most recent stock forecast was given by ANTHONY VENDETTI from MAXIM GROUP on 17-Jul-2024. First documented stock forecast 31-Oct-2016.

Best performing analysts who are covering RSLS - ReShape Lifesciences:

Kyle Rose Rick Wise Ben Haynor Anthony Vendetti

Currently out of the existing stock ratings of RSLS, 1 are a HOLD (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

10 months 16 days ago
(17-Jul-2024)

0/1 (0%)

$353075 (155.59%)

Buy

3 years 7 days ago
(26-May-2022)

0/2 (0%)

$442975 (103.74%)

Hold

$326250

$326245.09 (6644503.00%)

$326250

6 years 11 days ago
(22-May-2019)

2/2 (100%)

$-673750 (-67.38%)

303

Buy

$652500

$652495.06 (13289106.00%)

$543750

6 years 3 months 8 days ago
(25-Feb-2019)

2/2 (100%)

$-347500 (-34.75%)

195

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is RSLS (ReShape Lifesciences) average time for price targets to be met?

On average it took 124.5 days on average for the stock forecasts to be realized with a an average price target met ratio 50

Which analyst has the current highest performing score on RSLS (ReShape Lifesciences) with a proven track record?

KYLE ROSE

Which analyst has the current lower performing score on RSLS (ReShape Lifesciences) with a proven track record?

ANTHONY VENDETTI

Which analyst has the most public recommendations on RSLS (ReShape Lifesciences)?

Kyle Rose works at CANACCORD and has 16 price targets and 11 ratings on RSLS

Which analyst is the currently most bullish on RSLS (ReShape Lifesciences)?

Rick Wise with highest potential upside - $652495.06

Which analyst is the currently most reserved on RSLS (ReShape Lifesciences)?

Ben Haynor with lowest potential downside - -$0

ReShape Lifesciences in the News

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium

Vagal Neuromodulation Offers a Novel Approach to Treating Diabetes and Hypoglycemia Device Demonstrates the Ability to Modulate Glucose Levels Without Cardiac Side Effects, Overcoming a Key Limitation Of Conventional Vagal Stimulation Techniques IRVINE, Calif., May 02, 2025 (GLOBE NEWSWIRE) — ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today...

ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) — ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it has signed an agreement with Haifa, Israel-based Motion Informatics to exclusively import and distribute their next-generation neuromuscular rehabilitation devices in the U.S. The flagship product, the Stimel-03, was showcased...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?